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Primary effusion lymphoma (PEL) is a human her-
pesvirus 8 (HHV-8)-related neoplasm presenting with
recurrent effusions, usually in the absence of lymphade-
nopathy or organomegaly. Although most commonly
found in the setting of immunodeficiency, it is even
then rare, accounting for only 3% of all HIV-related
lymphoma (HRL) [1]. The prognosis of HIV-PEL
remains very poor despite the use highly active antire-
troviral therapy (HAART) and intensive regimens
incorporating methotrexate (MTX). The 2005 data
demonstrate a median survival of 6.2 months with a
1-year overall survival (OS) of 39.3% [2]. Few alterna-
tives exist for patients failing conventional therapy. A
limited literature of case series details experience with
autologous hemopoietic stem cell transplantation
(HSCT) for hematologic malignancies in HIV patients
[3]. Despite initial concerns regarding adequacy of stem
cell mobilization and perceived higher risk of opportu-
nistic infection, many sustained remissions have been
obtained, and it now appears that autologous transplan-
tation is a feasible approach in high-risk patients.
The literature is even more limited when contem-
plating allogeneic HSCT in the setting of HIV. Two
initial cases reports were of patients who had under-
gone allogeneic HSCT and were retrospectively found
tohaveHIV [4,5].Of these reportedpatients, 1 had suc-
cumbed to opportunistic infection 8months posttrans-
plant (transplanted in 1992) [4], and the other was alive
3 years posttransplantation (transplanted in 1996) [5].
Another patient in 1992 died at day 48 from hepatore-
nal failure after an allogeneic HSCT performed in an
attempt to treat the patient’s HIV [6]. Two patients
are reported to have undergone sibling reduced-inten-
sity conditioning (RIC) HSCT, both attaining com-
plete remission (CR) with minimal transplant-related
toxicity [7]. The first patient, with secondary acute
myelogenous leukemia (AML), was in CR at 2 years,
whereas the other, with refractory Hodgkin disease,
died of relapsed disease at 12 months. Finally, we
note a report of a patient who underwent allogeneic
HSCT from a matched unrelated donor (MUD) forsevere aplastic anemia (AA) [8]. HAART was interrup-
ted until after engraftment because of concerns of po-
tential negative impact on engraftment. He had a very
turbulent posttransplant course that included a period
of intubation. It is unclear whether the multiple cranial
nerve palsies suffered by this patient were a manifesta-
tion of critical illness polyneuropathy or whether they
could be attributed to the expected rise in HIV viral
load after interruption of HAART. Nevertheless, the
patient was alive at 12 months with an excellent perfor-
mance status and recovery of his neuropathy.
We managed a 34-year-old homosexual male who
presented in April 2004 with recurrent abdominal asci-
tes. PEL was diagnosed on the basis of ascitic fluid cy-
tology. HIV infection was diagnosed at this time. His
CD4 count was \10  106/L (500-1650  106/L),
and HIV viral load was noted to be 60,300 copies/
mL. He was commenced on a HAART regimen com-
prising lopinavir/ritonavir, tenofovir, and lamivudine.
He obtained CR with EPOCH [9] chemotherapy but
suffered an early relapse of his malignant abdominal
ascitis. He then attained CR2 with F-GIV [10]
chemotherapy. The remission was consolidated with
BEAM [11] autologous HSCT. This procedure was
complicated by presumed Pneumocystis jerovici
infection, which was successfully treated with high-
dose cotrimoxazole.
Chemotherapy was well tolerated, and an excellent
performance status was maintained throughout. It is
possible that our patient may have remained in CR af-
ter autologous HSCT, but given the poor prognosis of
HIV-related PEL it was considered that allogeneic
transplantation may represent a better chance for sus-
tained remission or cure. The patient had an HLA
compatible, HIV negative brother. RIC allogeneic
HSCT was recommended, given the poor results of
fully myeloablative transplantation in HIV positive
patients. The patient was appraised of the risks and
lack of data for allogeneic transplantation in this
setting, but was keen to proceed.
In June 2005 he underwent RIC allogeneic HSCT
with peripherally obtained stem cells, CD34 dose 2.38
 106/kg. The regimen consisted of melphalan 140
mg/m2 and fludarabine 30 mg/m2  5 conditioning
with tacrolimus 0.02mg/kg daily, sirolimus 1mg daily,
and methotrexate 5 mg/m2 (days 1, 3, 6, and 11)
for graft-versus-host disease (GVHD) prophylaxis.
Antimicrobial prophylaxis was with gancyclovir,
norfloxacin, cotrimoxazole, acyclovir, fluconazole,
and azithromycin. CMV PCR surveillance was
performed. Ursodeoxycholic acid and heparin were601
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tantly, his HAART was continued.
Platelet and neutrophil engraftment was at days 13
and 17, respectively. He had grade 1 skin GVHD post-
engraftment, resolving with prednisone tapered from 1
mg/m2 daily. He was discharged on day 20 without sig-
nificant infective complication. His CD4 count was
240  106/L at day 47 with an undetectable HIV viral
load. There has been no further GVHD. There was
full donor engraftment by 1 month. He remains in
CR2 31 months posttransplantation, has returned to
work, and remains only on HAART with HIV viral
load remaining undetectable throughout.
This case has been presented for 2 reasons. First, it
is an example of successful allogeneic HSCT in the
HIV setting. Second, this is the first report that we
are aware of in which a patient has undergone alloge-
neic HSCT for PEL in either the HIV or non-HIV
setting. HIV lymphoma is likely to remain a significant
problem forHIVpatients despiteHAART, and it is im-
portant that a full range of options is available. It does
appear that RIC allogeneic HSCT is 1 such option.REFERENCES
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